All News

pssfing.jpg

Predictors and Outcomes in Systemic Sclerosis

EurekAlert!

The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.

Read Article
vaccination.jpg

Safety of Recombinant Zoster Vaccine in Rheumatic Patients

EurekAlert!

New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells.

Read Article
lupus SLE

Social Determinants of Health in SLE

EurekAlert!

Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases.

Read Article
EULAR,poster

EULAR 2025 – Day 2 Report

Jack Cush, MD

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.

Read Article
psA.fil_.toes_.jpg

Psoriatic Arthritis: Hit hard and Early

EurekAlert!

Two recent studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate2,3, but these did not select for poor prognosis.

Read Article
About #Multidisciplinarity ... Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care #quotes #EULAR2025 #Invitedspeaker #outofthebox @RheumNow @epirheum https://t.co/RG6xpHejv9

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Dr. John Cush RheumNow ( View Tweet)

Diagnostic delay in #SpA 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay was 6.6 years 🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA 🔹️Associated with type of initial symptoms (shorter in peripheral) POS0909 #EULAR2025 @rheumnow https://t.co/3BMYFxbKiq

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

#neuromodulation in #rheumatoid #arthritis What is it? 👇 Autonomic & immune system interaction Who seeks this Rx? desperate pts w pain No Rx left Interested in technology #EULAR2025 @RheumNow @eular_org #D2T #RA https://t.co/XWWFiUK6Em

Links:

Janet Pope Janetbirdope ( View Tweet)
The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases? A thread 🧵👇🏼 @RheumNow #EULAR2025 https://t.co/KLZN9MvcFy

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
So we used to get taught about bimodal age distribution of RA onset - young people and old people. Actually, it’s early middle age where RA diagnoses have now grown globally over 30y - right in peak productivity Global Burden of Disease data #EULAR2025 OP0240-HPR @RheumNow https://t.co/8yyrex00yy

Links:

David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Dr. John Cush RheumNow ( View Tweet)

GRAPPA defines : - D2T-PsA (failed ≥3 therapies incl. ≥2 b/tsDMARDs) - CM(complex to manage)-PsA (adds pain, comorbidity, complexity). A needed framework to improve trial design & real-world care. Do these definitions fit your clinic? #OP0175 @RheumNow #EULAR2025 https://t.co/ot1bVLIYLA

Links:

Jiha Lee JihaRheum ( View Tweet)
Rheumatology #AI to optimize rheumatology triage. Only 53 percent correlation between the AIs diagnosis with rheumatologists final diagnosis. Not sure if we want 47 percent pts to drop off...without a chance for diagnosis? #POS0883 #EULAR2025 @RheumNow https://t.co/UWsCHG00t1

Links:

Bella Mehta bella_mehta ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

OP0176: Among D2T PsA pts, 43% lacked inflammation on imaging—despite symptoms. Clinical + US split them into PIPsA vs NIPsA, helping distinguish who needs escalation vs who doesn’t. A step toward smarter care in D2T PsA. @RheumNow #EULAR2025 https://t.co/E9igwvDPPN

Links:

Jiha Lee JihaRheum ( View Tweet)
OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all? In >1,100 RA pts, no link to liver fibrosis (FIB-4/APRI), modest ALT ↑, and fewer hospitalizations. real-world safety data worth a second look. @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

Yes, it is relevant to ask patients about physical joint strain in RA and propose strain specific interventions In ACPA+ RA pts for each 10% increase in strain, 7% increase in SJC44 and 5% MRI inflammation POS0166 #EULAR2025 @RheumNow https://t.co/jwpi7S8JTW

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Fast track PMR clinics in Denmark led to more patients seen, and time to referral went down. If we don’t get in early with a right diagnosis (and maybe early steroid-sparing) then PMR patients deteriorate. We shouldn’t let PMR be an end stage disease #EULAR2025 POS0136 @RheumNow https://t.co/pqwveamhJP

Links:

David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×